Heptares is a clinical-stage company creating novel medicines targeting G protein-coupled receptors (GPCRs), a superfamily of receptors linked to a wide range of human diseases. Our proprietary structure-based drug design platform has enabled us to build an exciting pipeline of new medicines with potential to transform the treatment of Alzheimer’s disease, schizophrenia, migraine, addiction, metabolic disease, and other indications. Our ability to address highly validated, yet historically undruggable, GPCRs has also attracted multiple partners including AstraZeneca, Cubist, Morphosys and Takeda.

Heptares is a wholly owned subsidiary of Sosei Group Corporation.

Latest News

Aug 6, 2015
Heptares and AstraZeneca Enter Agreement to Develop Novel Immuno-Oncology Treatments for a Range of Cancers
Jul 30, 2015
Heptares Initiates Proprietary Therapeutic Antibody Program against a GPCR Target
Events

Aug 16-20, 2015
American Chemical Society National Meeting
Boston, MA, USA
Presenting: Jon Mason

Sep 15-17, 2015
BioPharm America
Boston, MA, USA
Attending: Dan Grau

© 2012-2015 Heptares Therapeutics